Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

References

• Rutqvist, LE, Johansson, H. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among ‘high risk’ pre- and postmenopausal breast cancer patients. Acta Oncol 2006; (in press)
   Google Scholar
• Early Breast Cancer Trialist′s Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:1–15, 71–85.
   PubMedGoogle Scholar
• Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjöld B, Skoog L, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987; 10: 255–66
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Radiation therapy, chemotherapy and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials. Int J Radiation Oncol Biol Phys 1989; 16: 629–39
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Cedermark B, Fornander T, Glas U, Johansson H, Nordenskjöld B, et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989; 7: 1474–84
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990; 66: 89–96
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Stockholm Breast Cancer Study Group. Acta Oncol 1992; 31: 265–70
   PubMed Web of Science ®Google Scholar
• Wrange Ö, Nordenskjöld B, Silfverswärd C, Granberg P-O, Gustafsson J-Å. Isoelectric focusing of estradiol receptor protein from human mammary carcinoma. A comparison to sucrose gradient analysis. Eur J Cancer 1976; 12: 695–700
   PubMed Web of Science ®Google Scholar
• Fernö M, Borg Å, Norgren A. A comparison of two steroid receptor assays in breast cancer: Dextran-coated charcoal and isoelectric focusing. Anticancer Res 1983; 3: 243–6
   PubMed Web of Science ®Google Scholar
• Fernö M, Borg Å, Sellberg G. Enzyme immuno assay of estrogen receptor (ER) in breast cancer biopsy samples. A comparison with isoelectric focusing and detection of ER during tamoxifen treatment. Acta Radiol Oncol 1986; 25: 171–5
   PubMed Web of Science ®Google Scholar
• Burton KA. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of DNA. Biochem J 1956; 62: 315–22
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–10
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543–9
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Marubini E, Valsecchi MG. Competing risks. Statistics in practice: Analysing survival data from clinical trials and observational studies, V Barnett. John Wiley and Sons, ChichesterUK 1995; 331–63
   Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–48
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Roy Statist Soc B 1972; 34: 187–220
   Web of Science ®Google Scholar
• Baum M, Brinkley DM, Dossett JA, McPhersson K, Patterson JS, Rubens RD, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 2: 450
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Prescott R. Adjuvant tamoxifen therapy and receptor levels. Lancet 1985; 1: 573
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfverswärd C, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989; 1: 117–20
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, et al. Adjuvant tamoxifen in early-stage breast cancer: Effects on intercurrent morbidity and mortality. J Clin Oncol 1991; 9: 1740–8
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst ;;87 1995; 3: 645–51
   Google Scholar
• Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398–406
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutqvist LE, Sjöberg HE, Blomqvist L, Mattsson A, Glas U. Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 1990; 8: 1019–24
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutqvist LE, Glas U. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen. Cancer Treat Rep 1987; 71: 685–8
   PubMedGoogle Scholar
• Early Breast Cancer Trialist′s Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687–717
   PubMed Web of Science ®Google Scholar
• Rössner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984; 52: 339–46
   PubMed Web of Science ®Google Scholar
• Nordenskjöld B, Rosell J, Rutqvist LE, Malmström PO, Bergh J, Bengtsson NO, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial. J Natl Cancer Inst 2005; 97: 1609–10
   PubMed Web of Science ®Google Scholar